138 related articles for article (PubMed ID: 12678746)
1. Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles.
Long BH; Rose WC; Vyas DM; Matson JA; Forenza S
Curr Med Chem Anticancer Agents; 2002 Mar; 2(2):255-66. PubMed ID: 12678746
[TBL] [Abstract][Full Text] [Related]
2. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
[TBL] [Abstract][Full Text] [Related]
3. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle.
Moreau P; Anizon F; Sancelme M; Prudhomme M; Bailly C; Carrasco C; Ollier M; Sevère D; Riou JF; Fabbro D; Meyer T; Aubertin AM
J Med Chem; 1998 May; 41(10):1631-40. PubMed ID: 9572888
[TBL] [Abstract][Full Text] [Related]
4. Production, isolation and structure determination of novel fluoroindolocarbazoles from Saccharothrix aerocolonigenes ATCC 39243.
Lam KS; Schroeder DR; Veitch JM; Colson KL; Matson JA; Rose WC; Doyle TW; Forenza S
J Antibiot (Tokyo); 2001 Jan; 54(1):1-9. PubMed ID: 11269705
[TBL] [Abstract][Full Text] [Related]
5. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
[TBL] [Abstract][Full Text] [Related]
6. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
[TBL] [Abstract][Full Text] [Related]
7. Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue.
Bailly C; Qu X; Anizon F; Prudhomme M; Riou JF; Chaires JB
Mol Pharmacol; 1999 Feb; 55(2):377-85. PubMed ID: 9927631
[TBL] [Abstract][Full Text] [Related]
8. Formaldehyde-induced alkylation of a 2'-aminoglucose rebeccamycin derivative to both A.T and G.C base pairs in DNA.
Bailly C; Goossens JF; Laine W; Anizon F; Prudhomme M; Ren J; Chaires JB
J Med Chem; 2000 Nov; 43(24):4711-20. PubMed ID: 11101362
[TBL] [Abstract][Full Text] [Related]
9. DNA binding properties of the indolocarbazole antitumor drug NB-506.
Carrasco C; Vezin H; Wilson WD; Ren J; Chaires JB; Bailly C
Anticancer Drug Des; 2001; 16(2-3):99-107. PubMed ID: 11962518
[TBL] [Abstract][Full Text] [Related]
10. Syntheses and biological activities of rebeccamycin analogues with uncommon sugars.
Zhang G; Shen J; Cheng H; Zhu L; Fang L; Luo S; Muller MT; Lee GE; Wei L; Du Y; Sun D; Wang PG
J Med Chem; 2005 Apr; 48(7):2600-11. PubMed ID: 15801850
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, and cytotoxic activity of N(ind)-alkoxy derivatives of antibiotic arcyriarubin and dechloro-rebeccamycin aglycon.
Lakatosh SA; Balzarini J; Andrei G; Snoeck R; Lakatosh A; De Clercq E; Preobrazhenskaya MN
J Antibiot (Tokyo); 2002 Aug; 55(8):768-73. PubMed ID: 12374389
[No Abstract] [Full Text] [Related]
12. Rebeccamycin analogues bearing amine substituents or other groups on the sugar moiety.
Anizon F; Moreau P; Sancelme M; Laine W; Bailly C; Prudhomme M
Bioorg Med Chem; 2003 Aug; 11(17):3709-22. PubMed ID: 12901916
[TBL] [Abstract][Full Text] [Related]
13. Indolocarbazole protein kinase C inhibitors from rebeccamycin.
Fabre S; Prudhomme M; Sancelme M; Rapp M
Bioorg Med Chem; 1994 Feb; 2(2):73-7. PubMed ID: 7922125
[TBL] [Abstract][Full Text] [Related]
14. Syntheses and antiproliferative activities of rebeccamycin analogues bearing two 7-azaindole moieties.
Marminon C; Pierré A; Pfeiffer B; Pérez V; Léonce S; Renard P; Prudhomme M
Bioorg Med Chem; 2003 Mar; 11(5):679-87. PubMed ID: 12537997
[TBL] [Abstract][Full Text] [Related]
15. Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin.
Woo MH; Vance JR; Marcos AR; Bailly C; Bjornsti MA
J Biol Chem; 2002 Feb; 277(6):3813-22. PubMed ID: 11733535
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, biological evaluation, and molecular modeling studies of rebeccamycin analogues modified in the carbohydrate moiety.
Animati F; Berettoni M; Bigioni M; Binaschi M; Felicetti P; Gontrani L; Incani O; Madami A; Monteagudo E; Olivieri L; Resta S; Rossi C; Cipollone A
ChemMedChem; 2008 Feb; 3(2):266-79. PubMed ID: 18157856
[TBL] [Abstract][Full Text] [Related]
17. Cellular uptake and interaction with purified membranes of rebeccamycin derivatives.
Goossens JF; Hénichart JP; Anizon F; Prudhomme M; Dugave C; Riou J; Bailly C
Eur J Pharmacol; 2000 Feb; 389(2-3):141-6. PubMed ID: 10688977
[TBL] [Abstract][Full Text] [Related]
18. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicities of three rebeccamycin derivatives in the National Cancer Institute screening of 60 human tumor cell lines.
Moreau P; Holbeck S; Prudhomme M; Sausville EA
Anticancer Drugs; 2005 Feb; 16(2):145-50. PubMed ID: 15655411
[TBL] [Abstract][Full Text] [Related]
20. DNA binding and topoisomerase I poisoning activities of novel disaccharide indolocarbazoles.
Facompre M; Carrasco C; Colson P; Houssier C; Chisholm JD; Van Vranken DL; Bailly C
Mol Pharmacol; 2002 Nov; 62(5):1215-27. PubMed ID: 12391286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
